Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ANO2 | Q9NQ90 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19411026 | 0.87 | MEN1 (0.50) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL30154489 | 0.87 | MEN1 (0.50) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL28942782 | 0.86 | LMNA (0.48) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL3870178 | 0.85 | HSD17B10 (0.68) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL10864958 | 0.85 | CYP3A4 (0.61) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL3876888 | 0.85 | MEN1 (0.51) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL3869051 | 0.84 | MEN1 (0.55) | MEN1KMT2ALMNAALDH1A1GAA | |
| SCHEMBL3869208 | 0.83 | MEN1 (0.50) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL7133160 | 0.83 | MAPT (0.49) | MEN1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL967886 | 0.82 | L3MBTL1 (0.51) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010204-A1 | 2- and 2,5-substituted phenylketoenols | LIEB FOLKER (DE) | 2002-01-24 | — | — | US | claimed |
| US-11958858-B2 | Method for preparation of Asenapine | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-16 | — | — | US | disclosed |
| CN-110753691-B | Compounds for therapeutic and/or prophylactic treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11535628-B2 | Method for preparation of Asenapine | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| US-11535628-B2 | Method for preparation of Asenapine | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2022-12-27 | — | — | US | disclosed |
| EP-3630754-B1 | ISOINDOLINE-ACETYLENE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2022-07-27 | — | — | EP | disclosed |
| EP-4015519-A1 | METHOD OF PREPARING ASENAPINE | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2022-06-22 | — | — | EP | disclosed |
| US-20200102299-A1 | COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-04-02 | — | — | US | disclosed |
| CN-110753691-A | Compound (I) | 豪夫迈·罗氏有限公司 | 2020-02-04 | — | — | CN | disclosed |
| CN-110606852-A | Process for the preparation of asenapine | 浙江奥翔药业股份有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018220149-A1 | COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-06 | — | — | WO | disclosed |
| US-6596873-B1 | Pesticides, insecticides, herbicides and miticides | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-22 | — | — | US | disclosed |
| US-6504036-B1 | 2- and 2.5-substituted phenylketoenols | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-6359151-B2 | USE AS PESTICIDES. | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-19 | — | — | US | disclosed |
| US-20020010204-A1 | 2- and 2,5-substituted phenylketoenols | LIEB FOLKER (DE) | 2002-01-24 | — | — | US | disclosed |
| US-6255342-B1 | PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-03 | — | — | US | disclosed |
| US-6114374-A | USE AS PESTICIDES SUCH AS INSECTICIDES AND ACARICIDES; WELL TOLERATED BY CROPS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958858-B2 | Method for preparation of Asenapine | CYP3A5, QDPR, SPR | MEN1 2222/4885KMT2A 2211/4885LMNA 1191/4885 |
| US-20230159549-A1 | METHOD FOR PREPARATION OF ASENAPINE | CYP3A5, QDPR, SPR | MEN1 2222/4885KMT2A 2211/4885LMNA 1191/4885 |
| US-11535628-B2 | Method for preparation of Asenapine | CYP3A5, QDPR, SPR | MEN1 2222/4885KMT2A 2211/4885LMNA 1191/4885 |
| US-20200102299-A1 | COMPOUNDS | EGFR, ERBB2, ERBB3 | MEN1 3815/4885KMT2A 3597/4885LMNA 1605/4885 |
| US-20020010204-A1 | 2- and 2,5-substituted phenylketoenols | CYP1B1, CYP4X1, CYP1A1 | MEN1 4206/4885KMT2A 1169/4885LMNA 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.